Author: admin

Precision Fermentation Ingredients Market to Witness Rapid Growth: Industry Trends and Future Projections

“MarketsandMarkets™”
Precision Fermentation Ingredients Market by Ingredient (Whey & Casein Protein, Egg White, Collagen Protein, Heme Protein), Microbe (Yeast, Algae, Fungi, Bacteria) End User, Food & Beverage Application, and Region – Global Forecast to 2030

The global precision fermentation ingredients market is projected to grow from USD 2.8 billion in 2023 to USD 36.3 billion by 2030, reflecting a robust CAGR of 44.0% in value. This growth is driven by shifting consumer preferences toward veganism, rising protein consumption, and increased investments in innovation. Advances in genetic engineering have significantly enhanced the efficiency and sustainability of precision fermentation, enabling the reprogramming of microorganisms through synthetic biology to produce specialized food protein components cost-effectively.

Precision Fermentation Ingredients Market

Precision Fermentation Ingredients Market Growth Drivers

The growth of the Precision Fermentation Ingredients Market is driven by several key factors:

  • Rising Demand for Sustainable and Ethical Food Products: Consumers are increasingly concerned with sustainability, animal welfare, and environmental impacts. Precision fermentation offers a sustainable method to produce ingredients like proteins, flavors, and enzymes without relying on animal-based sources, driving demand in plant-based foods and other eco-friendly alternatives.
  • Advancements in Biotechnology and Fermentation Techniques: Continuous improvements in fermentation technology, such as more efficient microbial strains and enhanced fermentation processes, are reducing production costs and increasing the scalability of precision fermentation, making it an attractive option for ingredient production.
  • Growth of the Plant-based Food Industry: As plant-based food products gain popularity, there is a need for precision fermentation to create high-quality ingredients like proteins and enzymes that can be used to replicate the taste, texture, and nutritional profile of animal-derived products.
  • Rising Demand for Alternative Proteins: The global shift towards plant-based diets and the search for sustainable protein sources is propelling the demand for precision fermentation-derived proteins like those found in meat alternatives, dairy-free products, and other functional foods.
  • Regulatory Support for Biotech Innovations: Governments around the world are providing funding and favorable regulations for the development of innovative food production methods, including precision fermentation. This regulatory environment helps to reduce barriers to market entry and drives investment in the sector.
  • Consumer Preferences for Healthier and Clean Label Products: The growing preference for clean label foods with fewer artificial additives and more natural ingredients is benefiting precision fermentation, as it can provide ingredients that align with this trend.
  • Increased Investment from Major Corporations: Large food and beverage companies are investing heavily in precision fermentation to expand their product portfolios and gain a competitive edge in the rapidly growing market for alternative ingredients and food solutions.

 

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=30824914

Cosmetics & Others Segment to Lead with the Highest CAGR

The cosmetics & others segment is set for remarkable growth, projected to achieve the highest CAGR in the precision fermentation ingredients market. This surge aligns with the 2022 cosmetic trend, emphasizing the long-term benefits of fermented products. These formulations enhance skin absorption by breaking down substances, allowing vital nutrients to penetrate more effectively than non-fermented alternatives. A key player in this space, Geltor specializes in fermented ingredients for hair and skincare, further driving the segment’s expansion.

Meat & Seafood Segment to Dominate in Food & Beverage Applications

The meat & seafood segment is expected to witness the highest CAGR within the food & beverages precision fermentation ingredients market. This innovative approach leverages microorganisms like yeast, bacteria, fungi, and algae to produce plant-based proteins and fats, creating meat alternatives that replicate traditional textures, juiciness, and nutrition. The rising consumer preference for sustainable, health-conscious food choices is fueling the growth of this segment, reflecting the market’s shift towards environmentally friendly and nutritious options.

Request Sample pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=30824914

Heme Protein Segment to Experience Unprecedented Growth

Heme protein is projected to be the fastest-growing segment in the precision fermentation ingredients market, driven by advancements in microbial fermentation. This process primarily uses genetically modified yeast strains, such as Saccharomyces cerevisiae, to produce heme proteins in a sustainable and efficient manner, eliminating reliance on animal-derived sources. The United States remains a hub for research and development in this field, particularly in heme production for plant-based meat alternatives. Industry leaders like MycoTechnology Inc. and Impossible Foods are at the forefront of this innovation, showcasing the growing demand for fermentation-driven solutions across the alternative protein landscape.

The Asia Pacific region is dominate the precision fermentation ingredients market share.

This growth is driven by rapid urbanization and shifting consumer lifestyles, which have fueled demand for specialized products like alternative proteins and sustainable ingredients—key areas where precision fermentation excels. The region’s strong emphasis on technological advancements and innovation further supports the expansion of this market, creating a dynamic ecosystem for research and development. Additionally, consumers across Asia Pacific are increasingly open to adopting innovative products, demonstrating not just curiosity but active purchasing intent. Furthermore, rising investments and business expansions in the region are contributing to the market’s accelerated growth.

Top 10 Companies in the Precision Fermentation Ingredients Market

  • Geltor (US)
  • Perfect Day, Inc. (US)
  • The Every Co. (US)
  • Impossible Foods Inc. (US)
  • Motif FoodWorks, Inc. (US)
  • Imagindairy Ltd. (Israel)
  • Shiru, Inc. (US)
  • Formo (Germany)
  • Eden Brew (Australia)
  • Change Foods (US)

 

Geltor is a prominent bio-design firm that pioneers in advanced designer proteins. Integrating fermentation, biology, and protein optimization, Geltor produces sustainable and efficient alternative proteins with enhanced functionality. Their 100% animal-free and GMO-free ingredients are globally scalable and cultivated sustainably. Leveraging microbes, the company employs a fermentation process to create products using plant-based and renewable resources. In 2023, Geltor introduced Nucoll and Caviance, novel products catering to haircare and skincare needs. This evolution signifies a transformative approach to beauty and wellness, harnessing biotechnology’s potential for creating effective and eco-friendly alternatives.

Perfect Day, Inc. stands out as a prominent manufacturer of animal-free dairy products. It employs safe and established fermentation techniques to create animal-free whey protein using microflora. In contrast to conventional whey production methods, Perfect Day’s whey protein powder production achieves remarkable environmental efficiencies: a 99% reduction in water usage, a 97% decrease in greenhouse gas emissions, and approximately 60% lower non-renewable energy consumption. These figures are verified through ISO-compliant, third-party-reviewed life cycle assessments (LCAs). The company has established partnerships with multiple brands, expanding its presence in over 5,000 stores across the United States. Its market influence extends across North America and the Asia Pacific region as well.

Impossible Foods is engaged in providing plant-based fish, dairy, and meat products. The company’s product portfolio includes various plant-based products such as burgers, sausages, chicken nuggets, pork, and meatballs. Impossible Foods includes soy leghemoglobin manufactured through precision fermentation into its plant-based burger to provide the end product with the desired meat-like texture and taste. The company has its manufacturing facility located in Oakland, CA, US. Additionally, the company has partnered with one of the foremost food processing companies in the US, OSI Group, which provides extra manufacturing space to produce the popular Impossible Sausage and Impossible Burger. As a globally recognized entity, Impossible Foods serves customers across multiple countries, including the United States, Australia, Canada, Hong Kong, Macau, New Zealand, Singapore, the United Arab Emirates, and the United Kingdom.

Precision Fermentation Ingredients Industry News:

In May 2023, The EVERY Company and Alpha Foods officially entered into a Joint Development Agreement with the shared objective of bringing next-generation alt-meat products to the market. This collaboration aims to leverage EVERY’s trailblazing expertise in animal-free protein production and Alpha Foods’ renowned chef-crafted plant-based foods to accelerate advancements in taste and texture for non-animal products.

In March 2023, the partnership between The Hartman Group, Perfect Day, and Cargill enabled Perfect Day to gain valuable insights into consumer attitudes and preferences related to precision fermentation ingredients. This data has helped Perfect Day strengthen its position in the market, spearhead the Precision fermentation Alliance

In October 2022, Impossible Foods’ collaboration with Domino’s Australia, introducing Impossible™ Beef on their pizzas, strategically expands their market presence, boosts brand exposure, and appeals to environmentally conscious consumers.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

In addition, MarketsandMarkets SalesIQ enables sales teams to identify high-priority accounts and uncover hidden opportunities, helping them build more pipeline and win more deals with precision.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/precision-fermentation-market-30824914.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Precision Fermentation Ingredients Market to Witness Rapid Growth: Industry Trends and Future Projections

Pulmonary Arterial Hypertension Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Pulmonary Arterial Hypertension Pipeline Insight” report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in Pulmonary Arterial Hypertension pipeline landscape. It covers the Pulmonary Arterial Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pulmonary Arterial Hypertension therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Pulmonary Arterial Hypertension Treatment Landscape. Click here to read more @ Pulmonary Arterial Hypertension Pipeline Outlook

Key Takeaways from the Pulmonary Arterial Hypertension Pipeline Report

  • In March 2025:- United Therapeutics conducted a study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).
  • In March 2025:- Actelion announced a study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.
  • In March 2025: Merck Sharp & Dohme LLC announced a study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to
  • DelveInsight’s Pulmonary Arterial Hypertension Pipeline analysis depicts a robust space with 55+ active players working to develop 55+ pipeline treatment therapies.
  • The leading Pulmonary Arterial Hypertension Companies such as Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic and others.
  • Promising Pulmonary Arterial Hypertension Therapies such as TPN171H, Tadalafil, Treprostinil Palmitil, Satralizumab (Genetical Recombination), PF-07868489, Sotatercept and others.

Discover groundbreaking developments in Pulmonary Arterial Hypertension therapies! Gain in-depth knowledge of key Pulmonary Arterial Hypertension clinical trials, emerging drugs, and market opportunities @ Pulmonary Arterial Hypertension Clinical Trials Assessment

Pulmonary Arterial Hypertension Emerging Drugs Profile

  • Sotatercept: Acceleron Pharma

Sotatercept is a first-in-class therapeutic fusion protein comprised of the extracellular domain of human activin receptor type IIA, fused to the Fc domain of human immunoglobulin G1 (IgG1). It provides balance of the growth-promoting activin growth differentiation factor pathway, and the growth-inhibiting BMP pathway by serving as a ligand trap for the TGF-β superfamily. The United States Food and Drug Administration (FDA) has granted Orphan Drug designation and Breakthrough Therapy designation to sotatercept for the treatment of PAH; the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to sotatercept for the treatment of PAH. Sotatercept is in Phase III clinical trial for the treatment of PAH.

  • LIQ861: Liquidia Technologies

LIQ861 is an investigational, inhaled dry powder formulation of treprostinil designed using the Company’s novel PRINT technology and engineered with the goal of enhancing deep-lung delivery of treprostinil in PAH patients by means of a convenient, palm-sized dry powder inhaler. Liquidia resubmits New Drug Application for LIQ861 under the 505(b)(2) regulatory pathway for the treatment of pulmonary arterial hypertension (PAH).

The Pulmonary Arterial Hypertension Pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Pulmonary Arterial Hypertension with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Arterial Hypertension Treatment.
  • Pulmonary Arterial Hypertension Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Pulmonary Arterial Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pulmonary Arterial Hypertension market

Stay informed about the Pulmonary Arterial Hypertension pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Pulmonary Arterial Hypertension Unmet Needs

Pulmonary Arterial Hypertension Companies

Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic and others.

Pulmonary Arterial Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

Pulmonary Arterial Hypertension Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Transform your understanding of the Pulmonary Arterial Hypertension Pipeline! See the latest progress in drug development and clinical research @ Pulmonary Arterial Hypertension Market Drivers and Barriers, and Future Perspectives

Scope of the Pulmonary Arterial Hypertension Pipeline Report

  • Coverage- Global
  • Pulmonary Arterial Hypertension Companies- Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic and others.
  • Pulmonary Arterial Hypertension Therapies- TPN171H, Tadalafil, Treprostinil Palmitil, Satralizumab (Genetical Recombination), PF-07868489, Sotatercept and others.
  • Pulmonary Arterial Hypertension Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Pulmonary Arterial Hypertension Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Oncology Research–Access the Full Pulmonary Arterial Hypertension Pipeline Analysis Today! @ Pulmonary Arterial Hypertension Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Pulmonary Arterial Hypertension: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Pulmonary Arterial Hypertension – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Sotatercept: Acceleron Pharma
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. GB-002: Gossamer Bio
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Apabetalone: Resverlogix
  15. Drug profiles in the detailed report…..
  16. Preclinical/Discovery Stage Products
  17. R107: Radikal Therapeutics
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Pulmonary Arterial Hypertension Key Companies
  21. Pulmonary Arterial Hypertension Key Products
  22. Pulmonary Arterial Hypertension- Unmet Needs
  23. Pulmonary Arterial Hypertension- Market Drivers and Barriers
  24. Pulmonary Arterial Hypertension- Future Perspectives and Conclusion
  25. Pulmonary Arterial Hypertension Analyst Views
  26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pulmonary Arterial Hypertension Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Edible Oils Market Overview, Growth Drivers, Latest Trends, Opportunities, Key Segments, Top Companies, and Recent Developments

“MarketsandMarkets™”
Edible Oils Market by Type (Palm Oil, Soybean Oil, Sunflower Oil, Olive Oil, Rapeseed Oil), Packaging Type, Packaging Technology, Extraction Technology, Grade, Application, End Use, Distribution Channel and Region – Global Forecast to 2029

The global edible oils market is valued at USD 250.78 billion in 2024 and is expected to reach USD 306.92 billion by 2029, growing at a CAGR of 4.1% during the forecast period. Several key factors are driving this expansion, including rising consumer awareness of healthier cooking options and increasing disposable incomes.

Edible Oils Market

The growing preference for plant-based diets and sustainable food choices has fueled demand for nutrient-rich oils such as olive, sunflower, and coconut, known for their digestive benefits, essential fatty acids, and heart health advantages. Edible oils serve diverse culinary purposes, including frying, baking, dressings, and marinades.

Moreover, advancements in extraction technologies and product fortification with vitamins and antioxidants are opening new market opportunities. Rapid urbanization and shifting dietary habits in emerging markets across the Asia-Pacific and Africa are significantly contributing to the industry’s global growth.

Edible Oils Market Trends

Here are some key trends shaping the Edible Oils Market:

1. Growing Demand for Healthier Oils

· Consumers are shifting towards healthy oils like olive oil, avocado oil, and cold-pressed oils due to their nutritional benefits.

· Increased awareness of heart health, cholesterol control, and weight management is driving demand for oils rich in unsaturated fats, like canola and sunflower oil.

2. Rise of Functional and Fortified Edible Oils

· Fortification with omega-3, vitamin D, and antioxidants is gaining traction as consumers look for additional health benefits.

· Functional oils with anti-inflammatory and immune-boosting properties are entering the market.

3. Surging Popularity of Plant-Based and Sustainable Oils

· Sustainable and non-GMO oils (e.g., palm oil alternatives, algae oil) are in demand due to environmental concerns.

· Growth in plant-based diets is increasing the use of oils like coconut, flaxseed, and hemp oil in vegan food products.

4. Premiumization & Cold-Pressed Oils Boom

· Cold-pressed and extra virgin oils are gaining popularity due to their higher nutrient content and superior taste.

· Consumers are willing to pay a premium for organic and unrefined oils with minimal processing.

5. Expanding Industrial Applications

· The food industry is innovating with blended oils (e.g., olive and canola mix) for improved functionality.

· The cosmetics and personal care industry is also utilizing edible oils in skincare and haircare products.

Attractive Opportunities in the Edible Oils Market

· As urbanization increases, there is greater adoption of Western diets and convenience foods, boosting the consumption of edible oils in the region, especially in fast food and ready-to-eat meals.

· Collaborations and the introduction of new products are expected to present profitable prospects for industry participants in the next five years.

· Asia Pacific’s expanding population fuels the demand for edible oils, particularly in emerging markets like India and China, where consumer spending on processed foods is increasing.

· Government initiatives and subsidies in several Asia Pacific countries are supporting edible oil production and importation, ensuring affordable pricing and encouraging consumption among a broader demographic.

Soybean Oil Leads the Edible Oils Market by Type

Soybean oil holds the largest share in the edible oils market, driven by its extensive applications and nutritional benefits. Its widespread use in cooking, baking, and processed foods has fueled its growing demand. Rich in unsaturated fats, omega-3 fatty acids, and vitamin E, soybean oil supports heart health and boosts immunity, making it a preferred choice among health-conscious consumers.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198285285

Household Segment Witnesses Significant Growth in Edible Oils Market (2024-2029)

The household segment is experiencing strong growth in the edible oils market, fueled by rising population levels, increasing disposable incomes, and higher household consumption. As demand for edible oils in daily cooking surges, this segment continues to expand at a steady pace. According to the Government of India’s Ministry of Commerce & Industry (December 2023), domestic edible oilseed consumption is rising by approximately 10 LMT per year. This increase is primarily driven by a growing population and improved purchasing power, further supported by the expanding production capacities of edible oil manufacturers. With a robust domestic market and rising availability, the household segment is expected to maintain its upward trajectory alongside the global demand for edible oils.

Asia Pacific Poised for Rapid Growth in the Edible Oils Market (2024–2029)

The Asia-Pacific region is expected to witness the fastest growth in the edible oils market between 2024 and 2029, driven by a rising population, increasing disposable incomes, and a growing preference for healthier cooking oils. Key market players shaping this dynamic landscape include Wilmar International Ltd (Singapore), United Plantations Berhad (Malaysia), and the Adani Group (India).

A notable innovation in the region was introduced in June 2020 when United Plantations Berhad’s subsidiary, Unitate, launched NutroOlive—a unique blend of Extra Virgin Olive Oil and Red Palm Oil. This product is packed with carotenoids, monounsaturated fatty acids, antioxidants, and natural vitamins, making it an ideal choice for frying, baking, salad dressings, and general cooking. Additionally, NutroOlive has received sustainability certification from the Roundtable on Sustainable Palm Oil (RSPO), aligning with the increasing consumer demand for health-conscious and eco-friendly edible oils.

The surge in innovative and sustainable product offerings underscores the Asia-Pacific region’s position as a key driver of growth in the global edible oils market.

Top 10 Companies in the Edible Oils Market

· ADM (US)

· Bunge (US)

· Associated British Foods plc (UK)

· Wilmar International Ltd (Singapore)

· United Plantations Berhad (Malaysia)

· Sime Darby Berhad (Malaysia)

· BORGES AGRICULTURAL & INDUSTRIAL EDIBLE OILS, S.A.U. (Spain)

· Cargill Incorporated (US)

· GrainCorp (Australia)

· Hebany (UAE)

· ADM (US)

Edible Oils Industry News:

· In September 2024, ADM (US) acquired Vandamme Hungaria Kft (Hungary). This added a 700 metric ton/day non-GM multi-seed and corn germ processing facility. It will boost ADM’s capacity to fulfill the growing demand for non-GM edible oils in Europe while associated with its global sustainability efforts and increased commitment to food security throughout the world.

· In August 2024, Bunge (US) Launched Fiona Refined Sunflower Oil in Hyderabad, Telangana. It is further fortified with vitamins A, D, and E and boasts the novel VitoProtect formula, which increases vitamin transfer during cooking by as much as 50 percent compared with standard sunflower oils. This launch addressed increasing consumer demand for healthier oils to cook while maintaining nutritional value.

· In March 2023, Wilmar International Ltd. acquired the remaining 24% stake in Calofic Corporation (Vietnam), the leading producer and distributor of vegetable oils. This acquisition makes Calofic an indirect wholly owned subsidiary of Wilmar, enhancing its presence and market position in Vietnam. This shows that the company is committed to aggressively expanding its regional footholds.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

In addition, MarketsandMarkets SalesIQ enables sales teams to identify high-priority accounts and uncover hidden opportunities, helping them build more pipeline and win more deals with precision.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/edible-oils-market-198285285.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Edible Oils Market Overview, Growth Drivers, Latest Trends, Opportunities, Key Segments, Top Companies, and Recent Developments

Acute Respiratory Distress Syndrome Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Acute Respiratory Distress Syndrome Pipeline Insight” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Acute Respiratory Distress Syndrome pipeline landscape. It covers the Acute Respiratory Distress Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acute Respiratory Distress Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Acute Respiratory Distress Syndrome research. Learn more about our innovative pipeline today! @ Acute Respiratory Distress Syndrome Pipeline Outlook

Key Takeaways from the Acute Respiratory Distress Syndrome Pipeline Report

  • In March 2025:- PPD DEVELOPMENT LP conducted a study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress Syndrome (ARDS) utilizing a platform trial design. Participants will be randomized to receive either a placebo or one of the active treatments.
  • In March 2025:- BioAegis Therapeutics Inc. announced a study to evaluate the efficacy and safety of rhu-pGSN plus standard of care (SOC) in subjects with moderate-to-severe ARDS (P/F ratio ≤150) due to pneumonia or other infections. Potential subjects hospitalized with pneumonia or other infections are to be screened within 24 hours of diagnosis of ARDS.
  • DelveInsight’s Acute Respiratory Distress Syndrome Pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Acute Respiratory Distress Syndrome treatment.
  • The leading Acute Respiratory Distress Syndrome Companies such as Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio, Meridigen Biotech Co., Ltd., Dompé Farmaceutici S.p.A, Veru Healthcare, Windtree Therapeutics, MiNK Therapeutics, Avalo Therapeutics, Inc., Cynata Therapeutics Limited, Thiogenesis Therapeutics Inc., Arch Biopartners, Ibudilast, and others.
  • Promising Acute Respiratory Distress Therapies such as STSA-1002, Rhu-pGSN, Reparixin 600mg, Centhaquine, MRG-001, TTI-0102, Dexamethasone, and others.

Stay informed about the cutting-edge advancements in Acute Respiratory Distress Syndrome treatments. Download for updates and be a part of the revolution in cancer care @ Acute Respiratory Distress Syndrome Clinical Trials Assessment

Acute Respiratory Distress Syndrome Emerging Drugs Profile

  • GEn 1124: GEn1E Lifesciences

GEn 1124 is an investigative small molecule drug being developed in collaboration with GEn1E Lifesciences and Biomedical Advanced Research and Development Authority (BARDA),part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services to support the development of the company’s novel therapy for acute respiratory distress syndrome (ARDS), The drug candidate is mitogen activated protein kinase 14 inhibitors .Currently, the drug is in Phase II stage of its development for the treatment of acute respiratory distress syndrome.

  • ALT-100: Aqualung Therapeutics Corp.

ALT-100 is a “First in Man” immune-based monoclonal antibody (mAb) being developed by Aqualung Therapeutics Corp. ALT-100 antibody is a revolutionary, next generation antibody therapy. The humanized antibody has been developed and optimized by Fusion Antibodies’ revolutionary CDRx humanization and ADD develop ability platforms. This humanized monoclonal antibody will block systemic inflammation and will improve survival in the ARDS. ALT-100 inhibits eNAMPT binding to TLR4.Currently the drug is in Phase II stage of clinical trial for the treatment of acute distress respiratory syndrome.

  • STSA 1002: Staidson (Beijing) Biopharmaceuticals Co., Ltd

STSA 1002 is an investigative recombinant anti-human C5a IgG1 monoclonal antibody which acts by targeting complement C5a inhibitors C5a by specifically binding to anaphylatoxin C5a, C5a loses its ability to bind to receptors and blocks C5a-induced Biological functions, such as neutrophil chemotaxis, degranulation and oxygen respiratory burst, etc., while not affecting C5 cleavage and the formation of membrane attack complex (MAC), retaining the bacteriolytic and bactericidal functions of the complement system, thereby achieving the treatment of viruses, etc. Severe pneumonia, acute lung injury or acute respiratory distress syndrome caused by factors. It is administered through oral and subcutaneous route. Currently, the drug is in Phase I/II stage of its development for the treatment of acute respiratory distress syndrome.

  • Descartes 30: Cartesian Therapeutics

Descartes-30 is an off-the-shelf (allogeneic) MSC product engineered with Cartesian’s RNA ArmorySM cell therapy platform. Descartes-30 expresses a unique combination of DNases in patients and delivers a targeted treatment directly to the site of disease which eliminates neutrophil extracellular traps which are a key driver of inflammation and clotting in acute respiratory distress syndrome. The drug candidate relies on cell replacements mechanism of action. Currently the drug is in Phase I/II stage of clinical trial for the treatment of acute respiratory distress syndrome.

Learn more about Acute Respiratory Distress Syndrome Drugs opportunities in our groundbreaking metastatic prostate cancer research and development projects @ Acute Respiratory Distress Syndrome Unmet Needs

The Acute Respiratory Distress Syndrome Pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Acute Respiratory Distress Syndrome with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Respiratory Distress Syndrome Treatment.
  • Acute Respiratory Distress Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Acute Respiratory Distress Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Respiratory Distress Syndrome market

Acute Respiratory Distress Syndrome Companies

Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio, Meridigen Biotech Co., Ltd., Dompé Farmaceutici S.p.A, Veru Healthcare, Windtree Therapeutics, MiNK Therapeutics, Avalo Therapeutics, Inc., Cynata Therapeutics Limited, Thiogenesis Therapeutics Inc., Arch Biopartners, Ibudilast, and others.

Acute Respiratory Distress Syndrome Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical

Acute Respiratory Distress Syndrome Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

Discover the latest advancements in Acute Respiratory Distress Syndrome treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Acute Respiratory Distress Syndrome Market Drivers and Barriers, and Future Perspectives

Scope of the Acute Respiratory Distress Syndrome Pipeline Report

  • Coverage- Global
  • Acute Respiratory Distress Syndrome Companies- Staidson (Beijing) Biopharmaceuticals Co., Ltd, Cartesian Therapeutics, GEn1E Lifesciences, Aqualung Therapeutics Corp., Theratome Bio, Meridigen Biotech Co., Ltd., Dompé Farmaceutici S.p.A, Veru Healthcare, Windtree Therapeutics, MiNK Therapeutics, Avalo Therapeutics, Inc., Cynata Therapeutics Limited, Thiogenesis Therapeutics Inc., Arch Biopartners, Ibudilast, and others.
  • Acute Respiratory Distress Therapies- STSA-1002, Rhu-pGSN, Reparixin 600mg, Centhaquine, MRG-001, TTI-0102, Dexamethasone, and others.
  • Acute Respiratory Distress Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Acute Respiratory Distress Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Acute Respiratory Distress Syndrome pipeline on our website @ Acute Respiratory Distress Syndrome Emerging Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Acute Respiratory Distress Syndrome: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Acute Respiratory Distress Syndrome– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name: Company name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. GEn 1124: GEn1E Lifesciences
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. STSA 1002: Staidson (Beijing) Biopharmaceuticals Co., Ltd
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Acute Respiratory Distress Syndrome Key Companies
  21. Acute Respiratory Distress Syndrome Key Products
  22. Acute Respiratory Distress Syndrome- Unmet Needs
  23. Acute Respiratory Distress Syndrome- Market Drivers and Barriers
  24. Acute Respiratory Distress Syndrome- Future Perspectives and Conclusion
  25. Acute Respiratory Distress Syndrome Analyst Views
  26. Acute Respiratory Distress Syndrome Key Companies

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acute Respiratory Distress Syndrome Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Protheragen Unveils Revolutionary EndureCAR-T™ Cell Therapy Platform

“CAR-T Cell Therapy”
Protheragen offers a variety of CAR-T cell therapy services, including personalized CAR-T cell analysis and therapy regimens based on a variety of disease models.

Protheragen is an advanced CAR-T cell therapy service provider. With its extensive experience in cell therapy development and EndureCART™ technology platform, Protheragen provides investigators a wide range of disease models to ensure detailed and customized treatment methods for superior therapeutic outcomes.

With the development of immunology, scientists have come to recognize the potential of the immune system in recognizing and attacking cancer cells, especially the key role of T cells in anti-tumor immunity. Protheragen leverages this property of T cells to study and develop a variety of disease models to evaluate the effectiveness of immunotherapy and ensure optimal therapeutic outcomes through its innovative EndureCART™ technology.

In the field of tumor therapy, the emergence of CAR-T cell therapy provides a solution to the limitations of traditional treatment methods. CAR-T therapy works by genetically modifying one’s own T cells so that they can recognize and kill cancer cells more effectively. Therefore, this immunotherapy method has shown selectivity and high efficiency and has become a new direction for cancer treatment. Protheragen, a leading EndureCART™ technology provider, uses EndureCART™ to help researchers overcome the negative side effects that can occur in traditional oncology research and treatment approaches. This technology significantly improves the depth and breadth of cancer research.

In the research and application of CAR-T cell therapy, personalized therapy is an important direction in achieving the best efficacy. For different tumor characteristics and immune states, researchers need to develop customized treatment options to meet specific needs. Protheragen’s customized CAR-T cell therapy services are designed to provide research and development programs tailored to specific tumor characteristics and health conditions. This personalized approach helps to improve the pertinence and validity of the research.

In addition, the production process of CAR-T cells is complex and time-consuming, its therapeutic effect may be affected by a variety of factors, thus affecting the results of the study. To address this challenge, Protheragen is leveraging its extensive experience in hematologic tumor immunotherapy and its advanced EndureCART™ technology to enhance the efficacy and durability of CAR-T therapy and provide a more effective experimental basis for related studies.

Protheragen is committed to providing a one-stop CAR-T cell therapy development platform for researchers to choose the most suitable solution among many services. To ensure a quality service experience for customers, Protheragen has a professional consulting team ready to answer any questions and provide the necessary support and guidance to help them complete their research tasks. “Our goal is to provide more efficient solutions for our customers’ research projects through professional services and reliable technical support.” said the team at Protheragen.

Protheragen draws on its extensive expertise and advanced EndureCART™ technology to provide a diverse range of disease models for CAR-T cell therapy. At the same time, Protheragen provides customized CAR-T analysis and therapy services based on the needs of the investigators. This flexibility guarantees the validity and accuracy of the study results and promotes the development of CAR-T cell therapy research.

About Protheragen

As a provider of CAR-T research solutions, Protheragen offers a wide range of disease models and customized services for CAR-T cell therapy development using EndureCART™ technology platforms and comprehensive research services.

Media Contact
Company Name: Protheragen
Contact Person: Leona Reilly
Email: Send Email
Country: United States
Website: https://www.protheragen.us/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Protheragen Unveils Revolutionary EndureCAR-T™ Cell Therapy Platform

Hollywood Digest Magazine Editors Unveil the Top 10 Game-Changing Inventions of 2025

In a world where innovation drives convenience, the editors of Hollywood Digest have come together to curate a definitive list of the Top 10 Game-Changing Inventions of 2025 — must-have products designed to simplify everyday life. From smart home gadgets to revolutionary AI assistants, these cutting-edge solutions are set to transform the way we live, work, and navigate daily challenges.

Among the standout selections is The Toilet Stick, a brilliantly simple yet highly practical device that eliminates the need to touch toilet lids. Mounted on the wall for easy access, it provides a hygienic solution for homes, schools, hotels, and restaurants.

Learn more at thetoiletstick.net.

Four More Must-Have Innovations from the 2025 List:

• Smart Meal Planner – This intelligent app generates custom meal plans based on dietary needs and available ingredients, even creating a grocery list to make shopping effortless.

• AI-Powered Virtual Assistant for Seniors – A voice-activated companion designed to help older adults with daily tasks, medication reminders, and staying connected with loved ones.

• Automatic Pet Feeder with Camera – Ensures pets are fed on schedule, featuring a built-in camera and speaker so owners can check in and interact with their furry friends from anywhere.

• Compact Foldable Treadmill – A space-saving fitness solution that tucks away under a bed or in a closet, perfect for those looking to stay active without bulky equipment.

For the full list of game-changing inventions shaping 2025, visit Hollywood Digest here: Top 10 Game-Changing Inventions of 2025

Media Contact
Company Name: ICT PR
Contact Person: H Davidson
Email: Send Email
Country: United States
Website: www.iconnectyou.today

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hollywood Digest Magazine Editors Unveil the Top 10 Game-Changing Inventions of 2025

Unmanned Underwater Vehicles Market worth $11.1 Billion by 2030, at a CAGR of 15.0%

“Unmanned Underwater Vehicles Market”
The Unmanned Underwater Vehicles Market Value is projected to be USD 11.1 billion by 2030, growing from USD 4.8 billion in 2024, at a Compound Annual Growth Rate (CAGR) of 15.0% during the forecast period.

The report “Unmanned Underwater Vehicles Market by Type (Autonomous Underwater Vehicles (AUVs), Remotely Operated Vehicles (ROVs)), Product Type), Propulsion, Application, System, Speed, Shape, Depth and Region – Global Forecast to 2030” The market is valued at USD 4.8 billion in 2024 and is projected to reach USD 11.1 billion by 2030, at a CAGR of 15.0% from 2024 to 2030. The Unmanned Underwater Vehicles market is driven by the increasing technological advancement, increasing naval spending and increasing demand for UUVs for various commercial and defense applications. The increasing need of UUVs for oceanographic research, offshore oil and gas exploration, underwater infrastructure inspection, and maritime security is driving the market growth.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=140710720

Browse 473 market data Tables and 117 Figures spread through 417 Pages and in-depth TOC on “Unmanned Underwater Vehicles Market”

View detailed Table of Content here – https://www.marketsandmarkets.com/Market-Reports/unmanned-underwater-vehicles-market-140710720.html

Based on the ROV- system, the Propulsion systems segment is estimated to hold the highest market share during the forecast period.

Based on the ROV- systems, the propulsion systems segment is estimated to lead the Unmanned Underwater Vehicles Industry from 2024 to 2030. The propulsion systems segment is growing rapidly due to technological advancement in energy density of power sources, efficiency improvements in thruster design, and the integration of advanced control algorithms for precision maneuvering. Enhanced battery technologies, such as lithium-ion with higher energy densities, enable longer mission durations and increased operational range are driving the market growth of propulsion systems segment by ROV- systems.

Based on the AUV- system, the Payloads segment is estimated to hold the highest market share during the forecast period.

Based on the AUV- system, the Payloads segment is estimated to hold the highest market share during the forecast period. The growth of the segment is due to the advancements in sensor miniaturization, enhanced data processing capabilities, and the integration of multi-sensor fusion technologies. Innovations in high-resolution imaging sonars, and chemical sensors enables comprehensive environmental monitoring, resource exploration, and surveillance activities. The adoption of lightweight, energy-efficient components has increased the operational durations and payload capacities.

Based on regions, the Asia Pacific accounts for largest market share in Unmanned Underwater Vehicles market.

Based on region the Asia Pacific market is estimated to accounts for largest market share during the forecast period. There is increasing demand for the deployment of AUVs and ROVs for underwater exploration and surveillance for scientific research, defense and security applications, and offshore oil and gas exploration activities in the region. The rise in governmental and institutional investments in marine research and the development of maritime infrastructure are fueling the market growth in Asia Pacific region.

Key Players

The Unmanned Underwater Vehicles Companies is dominated by a few globally established players such as Kongsberg (Norway), Saab AB (Sweden), Boeing (US), Oceaneering International, Inc. (US) and Fugro (Netherlands).

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

In addition, MarketsandMarkets SalesIQ enables sales teams to identify high-priority accounts and uncover hidden opportunities, helping them build more pipeline and win more deals with precision.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Delray Beach
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/unmanned-underwater-vehicles-market-140710720.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Unmanned Underwater Vehicles Market worth $11.1 Billion by 2030, at a CAGR of 15.0%

Compact Construction Equipment Market Size & Forecast Report 2032

“Compact Construction Equipment Market”
Compact Construction Equipment Market by Type (Excavator, Loader, Skid Steer, Track Loader, Compactor, Telehandler), Propulsion, Power Output, Engine Capacity, Function, Electric Construction Equipment, Battery Chemistry, & Region – Global Forecast to 2032

The Compact Construction Equipment market size is projected to grow from USD 39.52 billion in 2025 to USD 56.05 billion by 2032, at a CAGR of 5.1%.

The compact construction equipment industry is expanding in North America due to increased regional residential and infrastructure spending, population expansion, and rising disposable income. Technological advancements in compact construction equipment, such as automation and telematics integration, will increase productivity, increasing the demand for new and advanced compact construction equipment.

“Mini Excavators will account for the largest share of compact construction equipment in 2025.”

Mini excavators are estimated to have the largest market share in the global compact construction equipment market in terms of value. Asia has a strong demand for mini excavators due the equipment’s ability to operate in diverse terrains and handle heavy loads, making them ideal for excavation, grading, and demolition tasks. Almost all construction equipment manufacturers offer mini excavators, and all manufacturers offer a variety of models in the product portfolios for this equipment. Kubota Corporation (Japan), Kobelco (Japan), and Caterpillar (US) lead the global market for Mini Excavators. Mini excavators offered by these companies fall in HP ranges from 20 HP to 70 HP. These lower power output equipment’s have major applications in residential sector. Mini excavators falling under this category have benefits such as low operating costs, better fuel efficiency, improved maneuverability and they are easy to control. Mini Excavators are also leading the shift to electrification. The majority of the OEMs developing electric-propelled equipment offer electric excavators. Industry experts say

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=89115103

“61-100 HP power output compact construction equipment to register the fastest growth during the forecast period.”

61-100 HP power output equipment is estimated to experience the fastest growth rate in the compact construction equipment market by power output. Skid Steers, backhoe loaders, and compact track loaders will dominate the market in this segment. This power output range is preferred in construction equipment because it can meet high torque and power demands. The demand for this range of equipment is particularly strong in Asian countries, driven by large-scale infrastructural development projects like roads, commercial complexes, and smart city projects. The major players in this category include JCB (UK), CNH Industrial (UK), Caterpillar (US), and Deere & Company (US). Recent developments in this segment include Kubota Corporation launching the SVL97-4 Compact Track loader in January 2025 and Deere & Company launching the 335 P-tier compact track loader in June 2024.

North America is estimated to be the largest compact construction equipment market.

North America is expected to be the largest market for compact construction equipment in the coming years. The rise in residential construction spending drives the growth of the compact construction equipment market in the region. The US is the major market in North America for compact construction equipment. As the population grows, there is a higher demand for new housing, boosting the need for construction equipment. In December 2024, the US approved 1.48 million building permits and completed 1.54 million housing units, with residential construction increasing by 2.6% from December 2023. The return of the Trump administration in the United States can have several significant impacts on the construction equipment market in the region. One of the key promises of Trump’s previous administration was a major push for infrastructure development, including roads construction, reconstruction of bridges and airports. The previous trump government also focused on imposing lower taxes on businesses and a more pro-business environment, which could lead to increased investments in both public and private infrastructure, creating demand for construction equipment. The negative factors from the new government maybe, Trump’s previous administration-imposed tariffs on a variety of products, including steel and aluminium, a similar return to these types of trade policies is expected, which will increase the costs of raw materials used in construction equipment manufacturing, such as steel and copper.

The Canadian construction equipment market is also expected to grow during the forecast period. In Canada, building construction investment grew by 2.8% to USD 21.4 billion in June 2024, and year-on-year investments rose by 10%. Mexico’s construction output also grew by 12.57% in June 2023 compared to the previous year. Hence, with the growing investments in the residential sector and the presence of major manufacturers like Caterpillar and Deere & Company in the region, the demand for compact construction equipment is estimated to be the highest.

Request Free Sample Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=89115103

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/compact-construction-equipment-market-89115103.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Compact Construction Equipment Market Size & Forecast Report 2032

Diabetic Retinopathy Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

DelveInsight’s, “Diabetic Retinopathy Pipeline Insight” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Retinopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Diabetic Retinopathy Treatment Landscape. Click here to read more @ Diabetic Retinopathy Pipeline Outlook

Key Takeaways from the Diabetic Retinopathy Pipeline Report

  • In March 2025:- Vantage Biosciences Ltd announced a study to evaluate the Efficacy and Safety of Orally Administered VX-01 in Diabetic Retinopathy of Non-Proliferative Type (NPDR).
  • In March 2025:- Invirsa Inc. announced a phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during a 12-week dosing period in subjects with non-center involved DME (NCIDME) associated with NPDR [Part 1] and during an 8-week dosing period in subjects with center-involved DME (CIDME) associated with NPDR [Part 1].
  • In March 2025:- Incepta Pharmaceuticals Ltd conducted a study to to Compare Efficacy & Safety Between Ranibizumab 10mg/ml Injection of Incepta and Lucentis in Patients With Diabetic Macular Edema by ITV Injection.
  • In March 2025:- EyePoint Pharmaceuticals Inc. announced a study of Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Diabetic Macular Edema (DME).
  • DelveInsight’s Diabetic Retinopathy pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Diabetic Retinopathy treatment.
  • The leading Diabetic Retinopathy Companies such as Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.
  • Promising Diabetic Retinopathy Pipeline Therapies such as Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine, and others.

Discover groundbreaking developments in Diabetic Retinopathy therapies! Gain in-depth knowledge of key Diabetic Retinopathy clinical trials, emerging drugs, and market opportunities @ Diabetic Retinopathy Clinical Trials Assessment

Diabetic Retinopathy Emerging Drugs Profile

  • Tarcocimab tedromer: Kodiak Sciences

Tarcocimab is an investigational anti-VEGF therapy built on Kodiak’s proprietary Antibody Biopolymer Conjugate (“”ABC””) Platform and is designed to maintain potent and effective drug levels in ocular tissues for longer than existing available agents. Kodiak’s objective with tarcocimab is to enable earlier treatment and prevention of vision loss for patients with diabetic retinopathy and to develop a new durability agent to improve outcomes for patients with retinal vascular diseases. Currently, the drug is in Phase III stage of its clinical trial for the treatment of diabetic retinopathy.

  • OTT166: Ocuterra Therapeutics

Nesvategrast (OTT166) is an investigational, novel, patented, potent and selective small molecule RGD integrin inhibitor designed with purpose engineering to have an optimum balance of physiochemical properties to allow it to distribute to the retina in high concentrations after topical (eye drop) administration to the eye. In preclinical studies, nesvategrast selectively inhibited key RGD integrin subtypes, including αvβ3, to regulate cellular responses to VEGF and other growth factors known to contribute to development and progression of diabetic retinopathy and other ocular diseases. In early clinical trials in patients with diabetic retinal disease, nesvategrast eye drops have demonstrated preliminary evidence of tolerability and biological activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diabetic retinopathy. 

  • APX3330: Apexian Pharmaceuticals

APX3330 is a first-in-class, small molecule, oral inhibitor of the transcription factor regulator Ref-1 (reduction-oxidation effector factor-1). With a novel dual mechanism of action, APX3330 blocks the downstream pathways those involving angiogenesis (VEGF) and inflammation (NFkB) to decrease abnormal activation of both angiogenesis, and of inflammatory pathways that are implicated across several ocular diseases, including DR, DME, and age-related macular degeneration (AMD). APX3330 has shown a favorable safety and tolerability profile in 12 clinical trials conducted in healthy, hepatitis, cancer, and diabetic subjects. Currently, the drug is in Phase II stage of its clinical trial for the treatment of diabetic retinopathy.

OTX-TKI: Ocular Therapeutix

OTX-TKI is an investigational bioresorbable, hydrogel implant incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic properties, being evaluated for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diabetic retinopathy.

The Diabetic Retinopathy Pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Retinopathy with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Retinopathy Treatment.
  • Diabetic Retinopathy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Diabetic Retinopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Retinopathy market

Stay informed about the Diabetic Retinopathy pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Diabetic Retinopathy Unmet Needs

Diabetic Retinopathy Companies

Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.

Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Diabetic Retinopathy Pipeline Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Transform your understanding of the Diabetic Retinopathy Pipeline! See the latest progress in drug development and clinical research @ Diabetic Retinopathy Market Drivers and Barriers, and Future Perspectives

Scope of the Diabetic Retinopathy Pipeline Report

  • Coverage- Global
  • Diabetic Retinopathy Companies- Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.
  • Diabetic Retinopathy Pipeline Therapies- Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine, and others.
  • Diabetic Retinopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Diabetic Retinopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Dive deep into rich insights for new drugs for Diabetic Retinopathy Treatment, Visit @ Diabetic Retinopathy Market Drivers and Barriers, and Future Perspective

Table of Content

  1. Introduction
  2. Executive Summary
  3. Diabetic Retinopathy: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Diabetic Retinopathy– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. KSI-301: Kodiak Sciences
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. RGX 314: Regenxbio Inc
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. OTX-TKI: Ocular Therapeutix
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Diabetic Retinopathy Key Companies
  21. Diabetic Retinopathy Key Products
  22. Diabetic Retinopathy- Unmet Needs
  23. Diabetic Retinopathy- Market Drivers and Barriers
  24. Diabetic Retinopathy- Future Perspectives and Conclusion
  25. Diabetic Retinopathy Analyst Views
  26. Diabetic Retinopathy Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/diabetic-retinopathy-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diabetic Retinopathy Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

Ashley Paul Shines Bright with New Pop Dance Single “Golden Tickets”

Dynamic Track Brings Together Top Talent for an Electrifying Sound

Pop sensation Ashley Paul is turning up the heat with her latest single, Golden Tickets — a vibrant dance anthem that’s destined to ignite dance floors worldwide. Known for her powerhouse vocals and magnetic energy, Ashley’s newest release is a high-octane storytelling anthem designed to captivate and inspire.

Golden Tickets was crafted by an exceptional team of industry talent. The track was co-written by Taylor Helgeson, best known for his work on Aaron Carter’s album “Love”, with production led by Dielog and Emma Oliver. Their combined expertise has resulted in an energetic, feel-good sound that blends pulsating beats with infectious melodies — the perfect recipe for dance music lovers.

With its upbeat tempo, empowering lyrics, and a mysterious, sultry intro, Golden Tickets encourages listeners to embrace life’s opportunities and chase their dreams fearlessly. As Ashley puts it, “Test your limits” — and so she does. The track’s dynamic production, coupled with Ashley Paul’s signature vocal style, creates an electrifying experience that’s sure to become a club favorite.

“I wanted Golden Tickets to be a celebration — something that makes people feel excited about seizing the moment and stepping into their best life,” said Ashley Paul. “2025 is the year we spin gold, turn our world around, and create something extraordinary. I’m incredibly grateful to the amazing writers and producers who helped bring this vision to life.”

Golden Tickets is now available on all major streaming platforms. Fans can also look forward to a visually stunning music video set to premiere soon, adding yet another layer of excitement to this highly anticipated release.

Exciting news for fans: Special remixes of Golden Tickets are set to drop in April, promising fresh new takes on this energetic hit.

Follow Ashley Paul’s journey and stay updated on upcoming performances and releases:

Instagram: @official_ashley_paul

Official Website: www.ashpaulmusic.com

Media Contact
Company Name: ICT PR
Contact Person: H Davidson
Email: Send Email
Phone: 323 513 4804
City: Los Angeles
State: CA
Country: United States
Website: www.iconnectyou.today

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ashley Paul Shines Bright with New Pop Dance Single “Golden Tickets”